Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Marketable Securities

Marketable Securities

12 Months Ended

Dec. 31, 2011

4.	Marketable Securities

Cost and fair value of the Company's marketable securities are as follows:

	Cost		Gross Unrealized			Fair
Securities available-for-sale	Basis		Losses			Value
December 31, 2011:
State and municipal obligations	$	1,950,000	$	-		$	1,950,000

December 31, 2010:
State and municipal obligations	$	2,453,960	$	(2,340	)	$	2,451,620

Amortized cost and fair value at December 31, 2011 by contractual maturity are shown below. Expected maturities will differ from contractual maturities because the Company may redeem certain securities at par.

	Cost		Fair
Maturity	Basis		Value
10 years or more	$	1,950,000	$	1,950,000

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References + Details